<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25947" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nonalcoholic Fatty Liver</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kudaravalli</surname>
            <given-names>Pujitha</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>John</surname>
            <given-names>Savio</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pujitha Kudaravalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Savio John declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25947.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Non-alcoholic fatty liver disease (NAFLD) is a broad term used to cover a spectrum of conditions that are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis or hereditary disorders. This activity reviews the etiology and pathophysiology of non-alcoholic fatty liver and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of non-alcoholic fatty liver disease.</p></list-item><list-item><p>Review the presentation of a patient with non-alcoholic fatty liver disease.</p></list-item><list-item><p>Summarize the treatment options for non-alcoholic fatty liver disease.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by non-alcoholic fatty liver disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25947&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25947">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25947.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Non-alcoholic fatty liver disease (NAFLD) is a broad term used to cover a spectrum of conditions that are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis or hereditary disorders. The definition of significant alcohol consumption has not been consistent. For&#x000a0;non-alcoholic steatohepatitis (NASH) clinical trials, it has been defined as ongoing or recent consumption of more than 14 standard drinks on average per week in women and more than 21 standard drinks on average per week in men. Non-alcoholic fatty liver disease is most often diagnosed incidentally on imaging or when it presents with complications. The prevalence of NAFLD in Western countries is around 20 to 30%.<xref ref-type="bibr" rid="article-25947.r1">[1]</xref>&#x000a0;NAFLD is considered to be the liver manifestation of metabolic syndrome. 50 to 70% of people with diabetes are found to have NAFLD.<xref ref-type="bibr" rid="article-25947.r2">[2]</xref></p>
        <p>NAFLD has several phases of progression, which include simple steatosis, steatohepatitis, fibrosis, cirrhosis, and ultimately could even progress to hepatocellular carcinoma.&#x000a0;The disease has a benign course; it is a silent liver disease when the only histological finding is steatosis. The presence of hepatic injury with inflammation with or without fibrosis constitutes non-alcoholic steatohepatitis (NASH).<xref ref-type="bibr" rid="article-25947.r1">[1]</xref><xref ref-type="bibr" rid="article-25947.r3">[3]</xref>&#x000a0;Please refer to the chapters on hepatitis and non-alcoholic steatohepatitis under the transplant hepatology section for a detailed discussion of this topic.</p>
      </sec>
      <sec id="article-25947.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Obesity, diabetes, dyslipidemias, insulin resistance, and metabolic syndrome are known to be associated with the development of non-alcoholic fatty liver disease (NAFLD).<xref ref-type="bibr" rid="article-25947.r3">[3]</xref>&#x000a0;A temporal association has also been shown between&#x000a0;inorganic arsenic exposure and the development of NAFLD reflected by elevated alanine transferase (ALT).<xref ref-type="bibr" rid="article-25947.r4">[4]</xref>&#x000a0;Due to its close association with metabolic syndrome, NAFLD correlates with cardiovascular risk factors, which also contributes to mortality in these patients in addition to end-stage liver cirrhosis and hepatocellular carcinoma.</p>
      </sec>
      <sec id="article-25947.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Non-alcoholic fatty liver disease (NAFLD) incidence is rapidly increasing, especially in Western countries. Rising obesity levels, increasing incidence of childhood obesity, sedentary lifestyles, consumption of unhealthy quick eats, and a longer lifespan are some of the likely contributors. The incidence and prevalence of NAFLD are underestimated as ultrasonography is commonly used to screen for fatty liver disease. The prevalence of NAFLD is 80% to 90% in obese adults, 30% to 50% in patients with diabetes mellitus, 90% or more in patients with hyperlipidemia, 3 to 10% in children, and as high as 40% to 70% among children with obesity.<xref ref-type="bibr" rid="article-25947.r5">[5]</xref></p>
      </sec>
      <sec id="article-25947.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Both environmental and genetic factors contribute to the development of non-alcoholic fatty liver disease (NAFLD) and its progression. First-degree relatives of patients with NAFLD are at higher risk than the general population. Histone amino-terminal ends maintain the chromatin structure and gene expression that is cAMP-responsive element-binding protein H (CREBH) or sirtuin (SIRT1). Genetic studies have shown that activation of SIRT1 is thought to play a role in the development of NAFLD. The trigger of the progression of NAFLD to cancer is via abnormal DNA methylation.<xref ref-type="bibr" rid="article-25947.r6">[6]</xref></p>
        <p>Day and James proposed a two-hit model of pathogenesis in 1998. The first hit is caused by insulin resistance, which leads to the accumulation of fat droplets that are triglycerides in the cytoplasm of hepatocytes, leading to the development of steatosis. Insulin resistance causes excess delivery of free fatty acid and triglycerides to the liver and decreased excretion leading to accumulation. Also, excess carbohydrates are a stimulus for de novo fatty acid synthesis in the liver.</p>
        <p>The second hit causing hepatocellular injury and the development of NASH is multifactorial. Excessive fatty acids in the liver make the liver more vulnerable to injury. Peroxisomal fatty acid oxidation, reactive oxygen species (ROS) production from the mitochondrial respiratory chain, cytochrome P450 metabolism of fatty acids, and hepatic metabolism of gut-derived alcohol are hypothesized to cause the injury. Obesity also contributes to the second hit as adipose tissue releases inflammatory mediators such as leptin, tumor necrosis factor (TNF)- alpha, and interleukin (IL)-6, causing hepatocyte damage. The hepatocytes undergo ballooning, cytoskeletal aggregation, apoptosis, and necrosis.<xref ref-type="bibr" rid="article-25947.r7">[7]</xref>&#x000a0;</p>
        <p>Insulin resistance is also a part of the second hit. The sinusoidal collagen deposition caused by the activation of hepatic stellate cells and the portal fibrosis caused by the ductular proliferation leads to the development and progression of NASH. These changes have correlated with insulin resistance, which is now believed to cause the progression of steatosis to NASH and progressive fibrosis.<xref ref-type="bibr" rid="article-25947.r8">[8]</xref></p>
      </sec>
      <sec id="article-25947.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Non-alcoholic fatty liver disease (NAFLD) is more than 5% of hepatocytes with fat droplets on liver biopsy. Functionally, the liver is subdivided into three zones; the classification is made based on the oxygen supply. Zone 1 has the highest oxygenation (oxygenated blood from hepatic arteries) and encircles the portal tracts, and zone 3 encircles the central veins where the oxygenation is poor.</p>
        <p>The American Association for the Study of Liver Diseases (AASLD) defined the histopathological abnormalities required in the diagnosis of NASH, which include steatosis (macro more than micro), lobular inflammation, and hepatocellular ballooning is seen most apparently in the zone 3 steatotic liver cells. Fibrosis, although not necessary for the diagnosis, is usually present. Some other findings seen are Mallory-Denk bodies (MDB, eosinophilic intracytoplasmic inclusions), megamitochondria, glycogenated nuclei, and iron deposition.<xref ref-type="bibr" rid="article-25947.r9">[9]</xref></p>
        <p>Fibrosis starts in the acinar zone 3 and has the appearance of chicken wire from the deposition of collagen and other extracellular matrices along the sinusoids. NASH-related cirrhosis is macronodular or mixed. When cirrhosis develops, the other histological features may not be evident.<xref ref-type="bibr" rid="article-25947.r8">[8]</xref></p>
      </sec>
      <sec id="article-25947.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with non-alcoholic fatty liver disease (NAFLD) could present with many non-specific symptoms way before the diagnosis is made, although most patients are asymptomatic. Fatigue is one of the most common presenting symptoms. Sharp or dull aching upper abdominal pain, thirst, bloating, and sleep disturbances.<xref ref-type="bibr" rid="article-25947.r10">[10]</xref>&#x000a0;Patients who develop NASH-associated cirrhosis, end-stage liver disease, or hepatocellular carcinoma (HCC) present with symptoms like:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Jaundice</p>
          </list-item>
          <list-item>
            <p>Pruritis</p>
          </list-item>
          <list-item>
            <p>Ascites</p>
          </list-item>
          <list-item>
            <p>Memory impairment</p>
          </list-item>
          <list-item>
            <p>Easy bleeding</p>
          </list-item>
          <list-item>
            <p>Loss of appetite</p>
          </list-item>
        </list>
        <p>The most common clinical sign is mild to moderate hepatomegaly. Advanced stages of the spectrum can demonstrate signs of end-stage liver disease, such as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Jaundice</p>
          </list-item>
          <list-item>
            <p>Spider angiomas</p>
          </list-item>
          <list-item>
            <p>Palmar erythema</p>
          </list-item>
          <list-item>
            <p>Caput medusae</p>
          </list-item>
          <list-item>
            <p>Gynecomastia</p>
          </list-item>
          <list-item>
            <p>Dupuytren contracture</p>
          </list-item>
          <list-item>
            <p>Ascites</p>
          </list-item>
          <list-item>
            <p>Petechiae</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25947.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Mildly elevated serum aminotransferases are the primary abnormality in non-alcoholic fatty liver disease (NAFLD), although the liver enzymes are normal in the majority of patients. The ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT) is less than 1. Gamma-glutamyl transferase (GGT), when elevated in non-alcoholic fatty liver disease (NAFLD), can be a marker of increased mortality, with the progression of the disease, hypoalbuminemia, hyperbilirubinemia, thrombocytopenia, and prolonged prothrombin time present due to hepatic synthetic dysfunction.</p>
        <p>Ultrasound of the abdomen is routinely used to evaluate fatty liver, but a liver biopsy is considered the gold standard for the diagnosis of NAFLD. A non-invasive clinical scoring system called NAFLD in metabolic syndrome (MS) score was developed to predict the development of NAFLD in patients with metabolic syndrome. The clinical predictors included are BMI greater than or equal to 25, AST/ALT greater than or equal to 1, type 2 diabetes mellitus, and obesity. The positive likelihood ratio of developing NAFLD is 2.32 (low when the score is less than 3), and the risk is 7.77 (high when five or more).<xref ref-type="bibr" rid="article-25947.r11">[11]</xref>&#x000a0;Some of the other scoring systems are NAFLD fibrosis score (NFS), FIB-4 (fibrosis-4) index, original ELF (enhanced liver fibrosis) test, AST-to-platelet ratio index (APRI), AAR, fibrometer, NAFLD-MS score.<xref ref-type="bibr" rid="article-25947.r12">[12]</xref></p>
      </sec>
      <sec id="article-25947.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Lifestyle changes are recommended for all patients with non-alcoholic fatty liver disease (NAFLD), even without NASH, as these patients have metabolic derangements and are at risk for the development of cardiovascular diseases. The recommendation is a weight loss of 3 to 5% in simple steatosis and a weight loss of 7% to 10% in NASH. Adequate control of risk factors like hyperlipidemia with statins (it also protects from cardiovascular risks) and hypertension and adequate glycemic control are required. Please refer to the chapters on hepatitis and non-alcoholic steatohepatitis under the transplant hepatology section for a detailed discussion of this topic.</p>
        <p>Patients with NASH are to be followed by hepatologists or gastroenterologists. NASH with cirrhosis requires hepatocellular carcinoma surveillance with an ultrasound every six months. Several clinical trials are being conducted using anti-fibrotic, anti-apoptotic, and immune therapies for the treatment of NAFLD.<xref ref-type="bibr" rid="article-25947.r13">[13]</xref></p>
      </sec>
      <sec id="article-25947.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of non-alcoholic fatty liver disease (conditions that can also cause hepatic steatosis) include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Alcoholic liver disease</p>
          </list-item>
          <list-item>
            <p>Hepatitis C, particularly genotype 3</p>
          </list-item>
          <list-item>
            <p>Wilson disease</p>
          </list-item>
          <list-item>
            <p>Medications such as amiodarone, methotrexate, tamoxifen, glucocorticoids, valproate, anti-retroviral agents for HIV</p>
          </list-item>
          <list-item>
            <p>Reye syndrome</p>
          </list-item>
          <list-item>
            <p>Mitochondrial hepatopathies</p>
          </list-item>
          <list-item>
            <p>Kwashiorkor/anorexia nervosa</p>
          </list-item>
          <list-item>
            <p>Mitochondrial disorders</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25947.s11" sec-type="Staging">
        <title>Staging</title>
        <p>The&#x000a0;grading and stages of non-alcoholic fatty liver disease (NAFLD) are described below<xref ref-type="bibr" rid="article-25947.r14">[14]</xref><xref ref-type="bibr" rid="article-25947.r15">[15]</xref><xref ref-type="bibr" rid="article-25947.r9">[9]</xref></p>
        <p>Grades:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 1 (mild): Steatosis up to 66%, occasional ballooning in zone 3, scattered polymorphs with or without lymphocytes, mild or no portal inflammation</p>
          </list-item>
          <list-item>
            <p>Grade 2 (moderate): Any degree of steatosis, obvious ballooning predominantly in zone 3, intralobular inflammation with polymorphs and chronic inflammation, and mild to moderate portal inflammation</p>
          </list-item>
          <list-item>
            <p>Grade 3 (severe): Panacinar steatosis, ballooning, and obvious disarray predominantly in zone 3, intralobular inflammation with scattered polymorphs with or without mild chronic and mild to moderate portal inflammation</p>
          </list-item>
        </list>
        <p>Stages:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 0: No fibrosis</p>
          </list-item>
          <list-item>
            <p>Stage 1: Zone 3 perisinusoidal fibrosis only</p>
          </list-item>
          <list-item>
            <p>Stage 2: Zone 3 perisinusoidal and periportal fibrosis</p>
          </list-item>
          <list-item>
            <p>Stage 3: Bridging fibrosis</p>
          </list-item>
          <list-item>
            <p>Stage 4: Cirrhosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25947.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with non-alcoholic fatty liver disease (NAFLD) exhibit increased mortality rates when compared to the general population. These patients have a high risk of mortality from cardiovascular causes as these patients have metabolic derangements. Cardiovascular causes of mortality are higher in these patients than liver causes.<xref ref-type="bibr" rid="article-25947.r13">[13]</xref>&#x000a0;NAFLD is a slowly progressive disease; simple steatosis is reversible and non-progressive, whereas NASH can progress to cirrhosis. Over a 13 year follow-up, the progression of cirrhosis presented in 41% in a study by Ekstedt et al.<xref ref-type="bibr" rid="article-25947.r16">[16]</xref>&#x000a0;A meta-analysis done by White et al. showed that in cohorts of NAFLD or NASH with few or no cases of cirrhosis, the risk of developing HCC was minimal at 0 to 3% over 20 years, and in cohorts with NASH with cirrhosis, the risk was high at 2.4 % over seven years.<xref ref-type="bibr" rid="article-25947.r17">[17]</xref></p>
      </sec>
      <sec id="article-25947.s13" sec-type="Complications">
        <title>Complications</title>
        <p>The most important complications of&#x000a0;non-alcoholic fatty liver disease (NAFLD) in the descending order are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiovascular disease</p>
          </list-item>
          <list-item>
            <p>Hepatocellular carcinoma</p>
          </list-item>
          <list-item>
            <p>End-stage liver disease</p>
          </list-item>
        </list>
        <p>The severity of these complications is proportional to the severity of the histological stage and grade of liver disease.</p>
      </sec>
      <sec id="article-25947.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education on dietary decisions and portions is essential. Nutrition and lifestyle education are the mainstays of therapy. During every healthcare provider encounter, the issues of food choices, food portions, and exercises, including weight-bearing exercises, should be emphasized and reviewed. The American Diabetes Association and other organizations offer excellent dietary and lifestyle advice.</p>
      </sec>
      <sec id="article-25947.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The incidence and prevalence of non-alcoholic fatty liver disease (NAFLD) are rising and will continue to grow due to increasing obesity and lifestyle changes. The management of NAFLD will require an interprofessional team that consists of a primary care provider, nurse practitioner, hepatologist or gastroenterologist, nutritionist, endocrinologist, and bariatrician. Primary prevention with adequate management of metabolic derangement is essential to prevent the rising incidence of NAFLD and its associated complications. To lower the risk of heart disease, patients should be urged to reduce body weight, discontinue smoking, eat a healthy diet, and participate in regular exercise.</p>
        <p>Management of NAFLD is optimal with an interprofessional healthcare team that includes providers, specialists, specialty-trained nurses, and, where appropriate, pharmacists. These different disciplines need to engage in open communication with the patient to ensure the best possible outcomes.</p>
      </sec>
      <sec id="article-25947.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25947&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25947">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/nonalcoholic-fatty-liver-fatty-liver/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25947">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25947/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25947">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25947.s17">
        <title>References</title>
        <ref id="article-25947.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mili&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stimac</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.</article-title>
            <source>Dig Dis</source>
            <year>2012</year>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>158</fpage>
            <page-range>158-62</page-range>
            <pub-id pub-id-type="pmid">22722431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis.</article-title>
            <source>Diabetes Metab J</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-45</page-range>
            <pub-id pub-id-type="pmid">30793550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aguilera-M&#x000e9;ndez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Nonalcoholic hepatic steatosis: a silent disease].</article-title>
            <source>Rev Med Inst Mex Seguro Soc</source>
            <year>2019</year>
            <month>Mar</month>
            <day>15</day>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>544</fpage>
            <page-range>544-549</page-range>
            <pub-id pub-id-type="pmid">30889343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frediani</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Naioti</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marsit</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Welsh</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among U.S. adolescents and adults: an association modified by race/ethnicity, NHANES 2005-2014.</article-title>
            <source>Environ Health</source>
            <year>2018</year>
            <month>Jan</month>
            <day>15</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">29334960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellentani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scaglioni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bedogni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of non-alcoholic fatty liver disease.</article-title>
            <source>Dig Dis</source>
            <year>2010</year>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-61</page-range>
            <pub-id pub-id-type="pmid">20460905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Campo</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gallego-Dur&#x000e1;n</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gallego</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD).</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Mar</month>
            <day>19</day>
            <volume>19</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">29562725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basaranoglu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuschwander-Tetri</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis.</article-title>
            <source>Gastroenterol Hepatol (N Y)</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>282</fpage>
            <page-range>282-291</page-range>
            <pub-id pub-id-type="pmid">28286458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunt</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Tiniakos</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Histopathology of nonalcoholic fatty liver disease.</article-title>
            <source>World J Gastroenterol</source>
            <year>2010</year>
            <month>Nov</month>
            <day>14</day>
            <volume>16</volume>
            <issue>42</issue>
            <fpage>5286</fpage>
            <page-range>5286-96</page-range>
            <pub-id pub-id-type="pmid">21072891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fukusato</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Nov</month>
            <day>14</day>
            <volume>20</volume>
            <issue>42</issue>
            <fpage>15539</fpage>
            <page-range>15539-48</page-range>
            <pub-id pub-id-type="pmid">25400438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoonsari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohammad Hosseini Azar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghavam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hatami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asobar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gholami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rajabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Safarnezhad Tameshkel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Amirkalali</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sohrabi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical Manifestations and Diagnosis of Nonalcoholic Fatty Liver Disease.</article-title>
            <source>Iran J Pathol</source>
            <year>2017</year>
            <season>Spring</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-105</page-range>
            <pub-id pub-id-type="pmid">29515630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saokaew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanchanasuwan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Apisarnthanarak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Charoensak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Charatcharoenwitthaya</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Phisalprapa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chaiyakunapruk</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score).</article-title>
            <source>Liver Int</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>1535</fpage>
            <page-range>1535-1543</page-range>
            <pub-id pub-id-type="pmid">28294515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Obika</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noguchi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and evaluation of nonalcoholic fatty liver disease.</article-title>
            <source>Exp Diabetes Res</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>145754</fpage>
            <pub-id pub-id-type="pmid">22110476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machado</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Cortez-Pinto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Non-alcoholic fatty liver disease: what the clinician needs to know.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>28</day>
            <volume>20</volume>
            <issue>36</issue>
            <fpage>12956</fpage>
            <page-range>12956-80</page-range>
            <pub-id pub-id-type="pmid">25278691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunt</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Janney</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Di Bisceglie</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Neuschwander-Tetri</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Bacon</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.</article-title>
            <source>Am J Gastroenterol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>94</volume>
            <issue>9</issue>
            <fpage>2467</fpage>
            <page-range>2467-74</page-range>
            <pub-id pub-id-type="pmid">10484010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.</article-title>
            <source>Metabolism</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>65</volume>
            <issue>8</issue>
            <fpage>1080</fpage>
            <page-range>1080-6</page-range>
            <pub-id pub-id-type="pmid">26775559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ekstedt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franz&#x000e9;n</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Mathiesen</surname>
                <given-names>UL</given-names>
              </name>
              <name>
                <surname>Thorelius</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Holmqvist</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bodemar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kechagias</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of patients with NAFLD and elevated liver enzymes.</article-title>
            <source>Hepatology</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>865</fpage>
            <page-range>865-73</page-range>
            <pub-id pub-id-type="pmid">17006923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25947.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Kanwal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>El-Serag</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>1342</fpage>
            <page-range>1342-1359.e2</page-range>
            <pub-id pub-id-type="pmid">23041539</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
